This is the current revision of this page, as edited by Maxim Masiutin(talk | contribs) at 07:00, 29 December 2023(Add: s2cid, pmc, pmid, pages, issue, volume, doi, date, authors 1-21. Removed proxy/dead URL that duplicated identifier. | Use this bot. Report bugs. | #UCB_CommandLine 539/8293). The present address (URL) is a permanent link to this version.
Revision as of 07:00, 29 December 2023 by Maxim Masiutin(talk | contribs)(Add: s2cid, pmc, pmid, pages, issue, volume, doi, date, authors 1-21. Removed proxy/dead URL that duplicated identifier. | Use this bot. Report bugs. | #UCB_CommandLine 539/8293)
THZ-P1-2[10] (covalent inhibitor) as well as BAY-091 and BAY-297[11] (reversible inhibitors) have been reported as potent and selective PIP4K2A inhibitors. BAY-091 fulfills the quality criteria for a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.[12]
Loijens JC, Boronenkov IV, Parker GJ, Anderson RA (1996). "The phosphatidylinositol 4-phosphate 5-kinase family". Advances in Enzyme Regulation. 36: 115–40. doi:10.1016/0065-2571(95)00005-4. PMID8869744.
Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (March 2007). "The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia". Genes, Brain and Behavior. 6 (2): 113–9. doi:10.1111/j.1601-183X.2006.00234.x. PMID17410640. S2CID32120485.
He Z, Li Z, Shi Y, Tang W, Huang K, Ma G, Zhou J, Meng J, Li H, Feng G, He L (August 2007). "The PIP5K2A gene and schizophrenia in the Chinese population--a case-control study". Schizophrenia Research. 94 (1–3): 359–65. doi:10.1016/j.schres.2007.04.013. PMID17555944. S2CID34716299.
Overview of all the structural information available in the PDB for UniProt: P48426 (Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha) at the PDBe-KB.